
|Articles|May 1, 2002
- Volume 0 0
Animal Protein May Protect Bone Mineral Density
Advertisement
A positive association between intake of animal protein and bone mineral density (BMD) among women aged 55 years and older was found in a study published in the April 2002 issue of the American Journal of Epidemiology. The study, which involved 572 women, showed that each 15-g/day increase in animal protein intake was linked to an increase in BMD of 0.016 g/cm2 at the hip, 0.012 g/cm2 at the femoral neck, 0.015 g/cm2 at the spine, and 0.010 g/cm2 in a total body measurement. In contrast, vegetable protein was negatively associated with BMD.
Articles in this issue
over 24 years ago
HOT OTC Introductions in 2001over 24 years ago
Making the "White" Choice: OTC Tooth-Whitening Productsover 24 years ago
Norelgestromin/ Ethinyl Estradiol (Ortho Evra)over 24 years ago
Lawyers Have Latitude in Closing Argumentsover 24 years ago
Incomplete Directions Can Lead to Dispensing Errorsover 24 years ago
Pharmacodynamic Drug Interactions with Ziprasidoneover 24 years ago
An Update on Hepatitis Cover 24 years ago
Medication Advice for Travelersover 24 years ago
Allergic Rhinitis: A Focus on Nonprescription Therapyover 24 years ago
Labor-Inducing Folklore Is Alive and WellAdvertisement
Related to this article

As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.

William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.

In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.

BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.

A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5

